Conference Coverage
Conference Coverage
BOLERO-2: Everolimus Plus Exemestane Delays Breast Cancer Progression
Major Finding: According to updated results median progression-free survival was 7.4 months for combination therapy patients and 3.2 months for...
Conference Coverage
Mini X-Ray Device Treats Nonmelanoma Skin Cancers
Major Finding: Approximately 93% of patients treated for nonmelanoma skin cancers with an electronic brachytherapy device had cosmetic results...
Conference Coverage
Screen Carotids After Head and Neck Radiation
Major Finding: The estimated risk for stenosis of the carotid arteries 3 years after irradiation for head and neck cancer was 18%.Data Source:...
Conference Coverage
Hepcidin Levels Predict ESA and IV Iron Responses
Major Finding: Forty-seven patients with lower serum hepcidin levels who received darbepoetin and four to five doses of intravenous iron had...
Conference Coverage
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
Major Finding: Estimated 2-year progression-free survival was 69% among patients randomized to CHOP chemotherapy with/without rituximab plus...
Conference Coverage
European Trial Upholds Use of Erlotinib in EGFR-Mutant Lung Cancer
Major Finding: Erlotinib resulted in a significant 63% reduction in the risk of progression, compared with standard chemotherapy (HR 0.37).Data...
Conference Coverage
Pemetrexed Continuation Maintenance Slows NSCLC Progression
Major Finding: Pemetrexed maintenance therapy plus best supportive care after pemetrexed/cisplatin induction reduced the risk of progression by 38...